At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
News Medical on MSN
Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes
While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...
T cells targeting an FLT3 mutation selectively eliminate clonally involved primary AML cells in vivo
Recurrent driver mutations in FMS-related receptor tyrosine kinase 3 (FLT3) occur in around one-third of patients with de novo acute myeloid leukemia (AML). Although most FLT3 mutations are secondary ...
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...
The US Food and Drug Administration today approved quizartinib (Vanflyta) for adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation. The FDA also approved the LeukoStrat ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The ...
NUP98-NSD1 and NUP98-KDM5A fusions are linked to poor prognosis in AML, affecting OS and EFS significantly. NUP98-NSD1 is more common in pediatric AML, necessitating alternative detection methods like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback